ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. $(RXST)$ today reported financial results for the quarter and full year ended December 31, 2025.
Strategic Highlights and Recent Developments
-- 2025 Light Adjustable Lens (LAL$(R)$ and LAL+(R)) unit sales increased 12% to 109,615 -- Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practice -- Light Delivery Devices (LDD(TM)) installed base expanded to 1,134, providing a strong foundation for future procedure growth -- RxSight's FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from contemporary toric IOLs, were accepted for publication in the Journal of Cataract & Refractive Surgery -- Regulatory approval received in Australia, expanding the company's addressable international opportunity
"Based on our fourth quarter results, we believe that the commercial initiatives implemented in the second half of 2025 are showing early signs of progress," said Ron Kurtz, President and Chief Executive Officer of RxSight. "While there is still more work ahead, full year LAL growth reflected strong adoption as physicians and patients recognize the value of the company's differentiated therapy. Our team remains committed to driving the disciplined execution that supports doctors as they deliver the benefits of high-quality customized vision to their patients."
Fiscal Year 2025 Financial Results
Full-year 2025 global sales of $134.5 million decreased 4% versus the prior year. LAL revenue growth of 12% was offset by a 48% decrease in LDD system sales compared to 2024.
2025 gross profit was $103.0 million, or 76.6% of revenue compared to gross profit of $98.9 million, or 70.7% of revenue in 2024. The increase in gross margin was primarily due to a greater percentage of revenue from LAL sales.
Operating expenses for 2025 were $151.2 million, an 11% increase compared to $135.8 million in 2024. The increase was driven primarily by strategic investments to support our expanding commercial and operational footprint, in addition to research and development and marketing activities. The company is building international infrastructure and maintains regulatory approvals for the RxSight system in North America, Europe, Singapore, South Korea and, most recently, Australia.
In 2025, net loss was $(38.9) million, or $(0.95) per share on a basic and diluted basis compared to a net loss of $(27.5) million, or $(0.71) per share on a basic and diluted basis in 2024. Adjusted net loss was $(7.3) million, or $(0.18) per share on a basic and diluted basis, in 2025, compared to an adjusted net loss of $(2.8) million, or $(0.07) per share on a basic and diluted basis in 2024.
As of December 31, 2025, cash, cash equivalents and short-term investments totaled $228.1 million.
Fourth Quarter Financial Results
In the fourth quarter of 2025, total revenue was $32.6 million, a decrease of 19% compared to $40.2 million in the fourth quarter of 2024, largely reflecting lower LDD revenue compared to record LDD placements in the prior year period. For the quarter, LAL revenue decreased 1% year over year, while LDD revenue decreased 72%. Sequential LAL procedure growth reflects steady activity across the installed base, supported in part by recent commercial initiatives and typical seasonal trends.
Fourth quarter gross profit was $25.3 million or 77.5% of revenue, a decrease of $3.5 million compared to gross profit of $28.8 million or 71.6% of revenue for the year-ago period. The increase in gross profit as percent of revenue was primarily driven by the favorable shift in product mix toward LAL sales.
Total operating expenses were $36.6 million, a 2% decrease from $37.4 million in the year-ago period. The decrease was driven by lower personnel costs, partially offset by continued investments to support LAL sales and advance the company's research and development pipeline.
In the fourth quarter of 2025, the company reported a net loss of $(9.2) million, or $(0.22) per basic and diluted share, compared to a net loss of $(5.9) million, or $(0.15) per basic and diluted share in the fourth quarter of 2024. Adjusted net loss in the fourth quarter of 2025 was $(1.3) million, or $(0.03) per basic and diluted share, compared to an adjusted net gain of $1.3 million, or $0.03 per basic and diluted share in the fourth quarter of 2024.
Unit Sales Summary
YoY QoQ
2025 YoY Q4 2025 Change Change
Units Change Units vs. Q4 vs. Q3
Product Sold vs. 2024 Sold 2024 2025
------------- ----------- ----------- ----------- ----------- -----------
Light
Adjustable
Lenses 109,615 +12% 28,611 (2%) +10%
------------- ----------- ----------- ----------- ----------- -----------
Light
Delivery
Devices 163 (47%) 25 (70%) 0%
------------- ----------- ----------- ----------- ----------- -----------
2026 Guidance
The company provided its full year 2026 financial guidance as follows:
-- Revenue of $120.0 to $135.0 million, reflecting lower year-over-year LDD
placements;
-- Gross margin of 70% to 72%, driven by higher per-unit manufacturing costs
associated with lower LDD production volumes;
-- Operating expenses of $150.0 million to $160.0 million; and
-- Non-cash stock-based compensation expense of $30.0 million to $32.0
million.
Conference Call
On Wednesday, February 25, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter and full year 2025 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight(R) Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens(R) (LAL(R) /LAL+(R) , collectively the "LAL"), RxSight Light Delivery Device (LDD(TM)) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including: statements regarding the company's expectations that commercial initiatives implemented in the second half of 2025 are showing early signs of progress; statements relating to 2025 LAL growth and adoption trends in the United States; and statements concerning the company's commitment to disciplined execution in support of physicians delivering customized vision solutions to their patients. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should, " "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
RxSight, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(In thousands, except share and per share amounts)
Three Months Ended
December 31, Year Ended December 31,
2025 2024 2025 2024
----------- ----------- ----------- -----------
Sales $ 32,607 $ 40,214 $ 134,479 $ 139,927
Cost of sales 7,344 11,426 31,470 40,984
---------- ---------- ---------- ----------
Gross profit 25,263 28,788 103,009 98,943
---------- ---------- ---------- ----------
Operating
expenses:
Selling,
general and
administrative 27,694 28,209 112,651 101,434
Research and
development 8,905 9,208 38,549 34,367
---------- ---------- ---------- ----------
Total
operating
expenses 36,599 37,417 151,200 135,801
---------- ---------- ---------- ----------
Loss from
operations (11,336) (8,629) (48,191) (36,858)
Other income
(expense), net:
Interest
expense (4) (5) (19) (21)
Interest and
other income 2,195 2,708 9,332 9,474
---------- ---------- ---------- ----------
Loss before income
taxes (9,145) (5,926) (38,878) (27,405)
Income tax expense 6 12 66 50
---------- ---------- ---------- ----------
Net loss $ (9,150) $ (5,938) $ (38,944) $ (27,455)
========== ========== ========== ==========
Other
comprehensive
(loss) income
Unrealized
(loss) gain on
short-term
investments (13) (344) (136) 180
Foreign
currency
translation
gain (loss) 5 (12) 23 (9)
---------- ---------- ---------- ----------
Total other
comprehensive
(loss) income (8) (356) (113) 171
---------- ---------- ---------- ----------
Comprehensive loss $ (9,159) $ (6,294) $ (39,057) $ (27,284)
========== ========== ========== ==========
Net loss per
share:
Basic and
diluted $ (0.22) $ (0.15) $ (0.95) $ (0.71)
Weighted-average
shares used in
computing net loss
per share:
Attributable to
common stock,
basic and
diluted 41,175,725 40,356,756 40,850,739 38,867,726
RxSight, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share amounts)
December 31, December 31,
2025 2024
-------------- --------------
Assets
Current assets:
Cash and cash equivalents $ 19,949 $ 16,706
Short-term investments 208,179 220,517
Accounts receivable 23,383 30,050
Inventories, net 31,559 22,009
Prepaid and other current assets 4,389 4,541
---------- ----------
Total current assets 287,459 293,823
Property and equipment, net 13,056 12,413
Operating leases right-of-use assets 9,959 11,217
Restricted cash 750 750
Other assets 590 360
---------- ----------
Total assets $ 311,814 $ 318,563
========== ==========
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 5,296 $ 4,544
Accrued expenses and other current
liabilities 19,795 20,358
Lease liabilities 1,162 974
---------- ----------
Total current liabilities 26,253 25,876
Long-term lease liabilities 9,878 11,322
Other long-term liabilities -- 127
---------- ----------
Total liabilities 36,131 37,325
---------- ----------
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value,
900,000,000 shares authorized,
41,242,005 shares issued and
outstanding as of December 31,
2025 and 40,428,220 shares issued
and outstanding as of December 31,
2024 41 40
Preferred stock, $0.001 par value,
100,000,000 shares authorized, no
shares issued and outstanding -- --
Additional paid-in capital 936,628 903,127
Accumulated other comprehensive
loss 53 166
Accumulated deficit (661,039) (622,095)
---------- ----------
Total stockholders' equity 275,683 281,238
---------- ----------
Total liabilities and
stockholders' equity $ 311,814 $ 318,563
========== ==========
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States ("GAAP"), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share
Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:
Three months ended
December 31, Year ended December 31,
2025 2024 2025 2024
-------------------- ----------- ----------- ----------- -----------
Common Stock
Numerator:
Net loss available
to stockholders,
basic and
diluted $ (9,151) $ (5,938) $ (38,944) $ (27,455)
Add:
Stock-based
compensation 7,818 7,282 31,612 24,635
---------- ---------- ---------- ----------
Adjusted net (loss)
income available to
common stockholders,
basic and diluted: $ (1,333) $ 1,344 $ (7,332) $ (2,820)
---------- ---------- ---------- ----------
Denominator:
Weighted-average
shares
outstanding,
basic 41,175,725 40,356,756 40,850,739 38,867,726
Weighted-average
shares
outstanding,
diluted 41,175,725 45,622,429 40,850,739 38,867,726
Adjusted net earnings
(loss) per share,
basic $ (0.03) $ 0.03 $ (0.18) $ (0.07)
Adjusted net earnings
(loss) per share,
diluted $ (0.03) $ 0.03 $ (0.18) $ (0.07)
(END) Dow Jones Newswires
February 25, 2026 16:05 ET (21:05 GMT)
Comments